Mr Matthew Fisher

All publications

Journal articles

• Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C , Junker-Jensen A et al (2024) Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7). View this article in WRRO
• Hodgson K, Orozco-Moreno M, Goode EA, Fisher M, Garnham R, Beatson R, Turner H, Livermore K, Zhou Y, Wilson L , Visser EA et al (2024) Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. eBioMedicine, 104. View this article in WRRO
• Mironov A, Fisher M, Narayanan P, Elsayed R, Karabulutoglu M & Akhtar N (2023) Rac1 controls cell turnover and reversibility of the involution process in postpartum mammary glands. PLoS Biology, 21(1).
• Brown AW, Holmes T, Fisher M, Tozer GM, Harrity JPA & Kanthou C (2018) Cover feature : Evaluation of sydnone-based analogues of Combretastatin A-4 phosphate (CA4P) as vascular disrupting agents for use in cancer therapy (ChemMedChem 24/2018). ChemMedChem, 13(24), 2600-2600. View this article in WRRO
• Harrity JPA, Brown A, Holmes T, Fisher M, Tozer G & Kanthou C (2018) Evaluation of sydnone-based analogs of combretastatin A-4 phosphate (CA4P) as vascular disrupting agents for use in cancer therapy. ChemMedChem, 13(24), 2618-2626. View this article in WRRO
• Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA & Chantry AD (2018) ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS One, 13(6). View this article in WRRO
• Byers RA, Fisher M, Brown NJ, Tozer GM & Matcher SJ (2017) Vascular patterning of subcutaneous mouse fibrosarcomas expressing individual VEGF isoforms can be differentiated using angiographic optical coherence tomography. Biomedical Optics Express, 8(10), 4551-4567. View this article in WRRO
• Shepherd J, Fisher M, Welford A, McDonald D, Kanthou C & Tozer G (2017) The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Oncotarget, 2017(8), 95648-95661. View this article in WRRO
• English WR, Lunt SJ, Fisher M, Lefley DV, Dhingra M, Lee Y-C, Bingham K, Hurrell JE, Lyons SK, Kanthou C & Tozer GM (2017) Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma. Cancer Research, 77(10), 2633-2646. View this article in WRRO
• Brown AW, Fisher M, Tozer GM, Kanthou C & Harrity JP (2016) Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.. Journal of Medicinal Chemistry, 59(20), 9473-9488. View this article in WRRO
• Williams LJ, Mukherjee D, Fisher M, Reyes-Aldasoro CC, Akerman S, Kanthou C & Tozer GM (2014) An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate. British Journal of Pharmacology, 171(21), 4902-4913. View this article in WRRO
• Akerman S, Fisher M, Daniel RA, Lefley D, Reyes-Aldasoro CC, Lunt SJ, Harris S, Bjorndahl M, Williams LJ, Evans H , Barber PR et al (2013) Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies. International Journal of Cancer, n/a-n/a.
• Harris S, Craze M, Newton J, Fisher M, Shima DT, Tozer GM & Kanthou C (2012) Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale. PLoS ONE, 7(5). View this article in WRRO
• Lunt SJ, Lefley DV, Fisher M, Daniel R, Kanthou C & Tozer G (2012) Abstract 5296: The role of VEGF receptors 1 and 2 on tumor vascularization and progression in single VEGF isoform expressing tumors. Cancer Research, 72(8_Supplement), 5296-5296.
• Harris S, Evans C, Burley E, Fisher M, Greaves CL, Kanthou C & Tozer GM (2012) Abstract 1371: Delineating the function of single VEGF isoforms using both proteomic and molecular approaches. Cancer Research, 72(8_Supplement), 1371-1371.
• Daniel RA, Fisher M, Flores-Merino MV, Battaglia G, Ryan AJ, Blakey DC & Tozer GM (2011) Abstract 3279: Effects of the isoforms of the angiogenic growth factor VEGF on neo-vascularization and tumor response to the tyrosine kinase inhibitor cediranib. Cancer Research, 71(8_Supplement), 3279-3279.
• Abigail WF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Serio CD, Naldini L, De Palma M, Tozer GM & Lewis CE (2011) Abstract 2849: Tie2-expressing macrophages (TEM) depletion may enhance the clinical efficacy of combretastatin A-4-phosphate (CA-4-P). Cancer Research, 71(8_Supplement), 2849-2849.
• Jane Lunt S, Akerman S, Hill SA, Fisher M, Wright VJ, Reyes‐Aldasoro CC, Tozer GM & Kanthou C (2011) Vascular effects dominate solid tumor response to treatment with combretastatin A‐4‐phosphate. International Journal of Cancer, 129(8), 1979-1989.
• Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM & Lewis CE (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. Journal of Clinical Investigation, 121(5), 1969-1973.
• Akerman S, Reyes-Aldasoro CC, Fisher M, Pettyjohn KL, Bjorndahl MA, Evans H & Tozer GM (2011) Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents. Medical Engineering and Physics, 33(7), 805-809. View this article in WRRO
• Akerman S, Reyes-Aldasoro CC, Fisher M, Pettyjohn KL, Björndahl MA, Evans H & Tozer GM (2010) Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents. Medical Engineering and Physics.

Conference proceedings

• Sheridan K, Doris E, Pimenta M, Falkov J, Fisher M, Muthana M, Shields D, Mains R, Eipper B, Buckley C & Wilson A (2024) Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS & RHEUMATOLOGY, Vol. 76 (pp 1864-1865)
• Hodgson K, Goode EA, Bastian K, Fisher M, Garnham R, Orozco-Moreno M, Scott E, Krishna R, Drake RR, Elliott DJ , Wang N et al (2023) Using glycan targeting drugs to block prostate cancer bone metastasis. GLYCOBIOLOGY, Vol. 33(11) (pp 1043-1043)
• Valluru MK, Mukherjee D, Fisher M, Madrigal-Esquivel C, Bradford J, Kanthou C, Tozer GM & English WR (2019) VEGFA isoform switching in soft tissue sarcoma is associated with decreased survival. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 100(4) (pp A41-A41)
• Lee YC, Claeyssens F, Fisher M, Lefley DV, Kanthou C, Tozer GM & English WR (2019) Differences in VEGFA isoform expression regulate modes of migration and their sensitivity to anti-VEGFA therapy. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 100(4) (pp A25-A25)
• English WR, Lunt SJ, Fisher M, Hurrell JE, Lefley DV, Mukherjee D, Daniel R, Lyons SK, Kanthou C & Tozer GM (2015) Abstract A57: Differential tumor cell expression of VEGF isoforms impacts on the tumor microenvironment, metastasis and radiation response in a mouse fibrosarcoma model. Cancer Research, Vol. 75(1_Supplement) (pp A57-A57)
• Williams L, Fisher M, Reyes-Aldasoro CC, Kanthou C & Tozer GM (2011) Abstract 1578: A critical role for RhoA-GTPase signaling in the tumor vascular disrupting action of combretastatin-A4-phosphate in vivo. Cancer Research, Vol. 71(8_Supplement) (pp 1578-1578)

Preprints

• Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, De Bono J, Nunns H, Bailey C , Juncker-Jensen A et al (2024) Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy, Cold Spring Harbor Laboratory.
• Mironov A, Fisher M, Elsayed R, Karabulutoglu M & Akhtar N (2022) Rac1 controls cell turnover and mammary gland reversibility in post-partum involution, Cold Spring Harbor Laboratory.